The online version of this article (https://doi.org/10.1186/s12878-017-0086-8) contains supplementary material, which is available to authorized users.
Abnormal fibrinogens can be caused by clinically silent hereditary mutations. A new case was detected accidentally in an 11-year-old girl when routine pre-operative coagulation tests were performed for nasal turbinate surgery.
The fibrinogen genes FGA, FGG and FGB were sequenced using standard protocols. The kinetics of fibrin formation were followed by turbidity at 350 nm. Purified fibrinogen was incubated with plasmin, and the degradation products analyzed by SDS/PAGE. The formation of fibrinogen-albumin complexes was analyzed by immunobloting. Fibrin structure was examined in a Nikon Eclipse TE 2000-U laser microscope. Secretion of the variant protein was analyzed directly by reverse phase-electrospray time of flight-mass spectrometry (TOF-MS).
DNA sequencing revealed a novel heterozygous g. 3057 C > T mutation in the FGA that predicts a p. Arg104 > Cys substitution, in the proband and her father. Both patients were asymptomatic with low functional and antigen fibrinogen concentrations. The proband’s plasma fibrinogen polymerization was almost normal, with a 12% decrease in the final turbidity, while, the father’s fibrin formation had a diminished slope and final turbidity (2.5× and 40%, respectively). Aα Arg104 is located at a plasmin cleavage site in the coiled-coil region of fibrinogen. However, the father’s fibrinogen plasmin degradation was normal. Although the exchanged Cys introduces an unpaired –SH, immunoblotting showed no fibrinogen-albumin complexes. Furthermore, the plasma clot structure observed by confocal microscopy appeared almost normal. TOF-MS showed that the variant Aα chain was underrepresented in plasma and made up only about 25% of the total.
The low expression of the Aα Arg104 > Cys chain in circulation could account for the observed hypodysfibrinogenemia.
Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med. 2002;126:499–505. PubMed
Casini A, Brungs T, Lavenu-Bombled C, Vilar R, Neerman-Arbez M, de Moerloose P. Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation. J Thromb Haemost. 2017;15:876–88
Zhang JZ, Redman CM. Role of interchain disulfide bonds on the assembly and secretion of human fibrinogen. J Biol Chem. 1994;269:652–8. PubMed
Niwa K, Takebe M, Sugo T, Kawata Y, Mimuro J, Asakura S, et al. A gamma Gly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Blood. 1996;87:4686–94. PubMed
Marchi R, Echenagucia M, Meyer M, Acosta M, Apitz R, Ruiz-Sáez A. Fibrinogen Maracaibo: Hypo-Dysfibrinogenemia Caused by a Heterozygous Mutation in the Gen that Encodes for the Fibrinogen Aα Chain (G.1194G>A: P.Gly13>Glu) with Diminished Thrombin Generation. J Blood Disorders Transf. 2014;5:1–5.
Kotlin R, Reicheltova Z, Maly M, Suttnar J, Sobotkova A, Salaj P, et al. Two cases of congenital dysfibrinogenemia associated with thrombosis - fibrinogen Praha III and fibrinogen Plzen. Thromb Haemost. 2009;102:479–86. PubMed
Hager K, Felicetti M, Seefried G, Platt D. Fibrinogen and aging. Aging (Milano). 1994;6:133–8.
Spada RS, Toscano G, Chiarenza S, Di Mauro S, Cosentino FI, Iero I, et al. Ischemic stroke and fibrinogen in the elderly. Arch Gerontol Geriatr Suppl. 2004;9:403–6. CrossRef
- A novel fibrinogen mutation: FGA g. 3057 C > T (p. Arg104 > Cys) impairs fibrinogen secretion
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II